My Meeting Experience: A Radiation Oncologist’s Perspective

My Meeting Experience: A Radiation Oncologist’s Perspective

Dr. Josephine Kang
Josephine Kang, MD, PhD, is a radiation oncologist with Weill Cornell Medicine who is attending the Genitourinary (GU) Cancers Symposium for the first time. In the following interview, Dr. Kang discusses what she hopes to learn during the Symposium, as well as sessions she’s looking forward to attending.

Daily News: What do you hope to learn during the GU Cancers Symposium?

Dr. Kang: Oncology research is progressing at a rapid pace, and it is an exciting time in particular for the treatment of GU malignancies. I am looking forward to updates of phase III trials in prostate cancer, both in the definitive and adjuvant settings, which can broaden understanding of disease management and impact daily practice. Moreover, my patients request information about the newest advances and findings, and this Symposium will be a great opportunity to stay informed on the latest data.

I am also eager to learn about updates in renal and urothelial malignancies, where checkpoint inhibitors have shown potential. Advances in these diseases will be thought provoking and will provide a basis for ongoing and future clinical trial designs.  

Daily News: What are your goals for the GU Cancers Symposium?

Dr. Kang: My goal is to make the most of the 3 days and to attend as many sessions as possible. I am also looking forward to viewing the Poster Sessions. I enjoy speaking with the presenters and learn a great deal from such discussions. We currently have several trials in GU malignancies open at Weill Cornell, and it will be useful to interact with colleagues across institutions and disciplines to compare ideas and results, so I can best inform my patients of their options, such as standard-of-care treatments and clinical trials.

[Read: My Meeting Experience: A Medical Oncologist’s Perspective]

Daily News: What are some sessions you plan on attending and why?

Dr. Kang: I’m hoping to attend as many sessions as possible, but in particular, I am looking forward to “Active Surveillance for Prostate Cancer,” (watch this session on Virtual Meeting:, as this is a highly relevant topic in my current clinical practice and, I’m sure, for radiation oncologists and urologists who see patients with low-risk prostate cancers. Particularly in light of the recent ProtecT trial results, I am eager to listen to the presenters and their interpretation of the recent data.

My favorite part of attending meetings is discovering how physicians in different institutions practice and delving into the rationale behind their clinical decision making. As a result, I’m also looking forward to attending “Challenging Cases in High Risk, Recurrent, and Advanced Prostate Cancer” (watch this session on Virtual Meeting: I’m sure it will be thought provoking and entail the presentation of challenging cases similar to what I may find in the clinic.

Finally, the keynote lecture on the “Emerging Impact of Genomics on the Clinical Management of Bladder Cancer” from David J. McConkey, PhD, (February 17) will be a highlight of the Symposium that I do not want to miss. I’m looking forward to hearing about ongoing research efforts in bladder cancer and advances in treatment.

Daily News: Why is it important that radiation oncologists attend the GU Cancers Symposium?

Dr. Kang: As a radiation oncologist, I work closely with urologists, medical oncologists, and radiologists and enjoy being part of an interdisciplinary care team. The GU Cancers Symposium provides the opportunity for radiation oncologists to meet with physicians across other disciplines and spend focused time learning about GU malignancies.  

About Dr. Kang: Dr. Kang is a physician–scientist at Weill Cornell Medicine with a background in microbiology. She is actively working with Silvia Formenti, MD, to explore the role of the human microbiome on immunity and response to cancer treatment. Her clinical expertise is on the use of stereotactic body radiation for the treatment of cancer, with a special focus on genitourinary malignancies. She has published multiple studies on long-term quality-of-life and disease outcomes for 5-fraction stereotactic body radiotherapy for prostate cancer.